Stance Capital LLC Buys 5,252 Shares of IDEXX Laboratories, Inc. $IDXX

Stance Capital LLC grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 302.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,987 shares of the company’s stock after buying an additional 5,252 shares during the period. IDEXX Laboratories makes up 1.6% of Stance Capital LLC’s portfolio, making the stock its 9th biggest position. Stance Capital LLC’s holdings in IDEXX Laboratories were worth $4,464,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of IDXX. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $26,000. WealthCollab LLC acquired a new position in IDEXX Laboratories during the second quarter valued at approximately $30,000. J.Safra Asset Management Corp bought a new stake in IDEXX Laboratories in the third quarter valued at approximately $31,000. Armstrong Advisory Group Inc. raised its holdings in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares during the period. Finally, Salomon & Ludwin LLC acquired a new stake in IDEXX Laboratories in the third quarter worth $35,000. 87.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

IDXX has been the subject of several research analyst reports. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. UBS Group decreased their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. BTIG Research lowered their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Finally, Piper Sandler dropped their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $586.98 on Wednesday. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The company’s fifty day simple moving average is $653.86 and its 200-day simple moving average is $666.03. The firm has a market cap of $46.68 billion, a PE ratio of 44.91, a P/E/G ratio of 3.56 and a beta of 1.66. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the business posted $2.53 EPS. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Michael G. Erickson sold 5,371 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the transaction, the executive vice president owned 12,693 shares in the company, valued at $7,963,334.34. This trade represents a 29.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares in the company, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 45,957 shares of company stock worth $29,862,109 over the last three months. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.